Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
äŒæ¥ã³ãŒãGNFT
äŒç€ŸåGenfit SA
äžå Žæ¥Dec 19, 2006
æé«çµå¶è²¬ä»»è
ãCEOãPrigent (Pascal)
åŸæ¥å¡æ°180
蚌åžçš®é¡Depository Receipt
æ±ºç®ææ«Dec 19
æ¬ç€Ÿæåšå°Parc Eurasante 885 avenue Eugene Avinee
éœåžLOOS
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœFrance
éµäŸ¿çªå·59120
é»è©±çªå·33320164000
ãŠã§ããµã€ãhttps://www.genfit.fr/
äŒæ¥ã³ãŒãGNFT
äžå Žæ¥Dec 19, 2006
æé«çµå¶è²¬ä»»è
ãCEOãPrigent (Pascal)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã